A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies.
Latest Information Update: 02 Oct 2014
At a glance
- Drugs MKC 1 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors CASI Pharmaceuticals; EntreMed
- 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.